NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company cited the absence of approved vaccines or therapies specifically targeting the virus strain, highlighting the urgent need for effective interventions.
NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical, according to the company. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc., under a Memorandum of Understanding. The company holds broad, exclusive, sub-licensable field licenses from TheraCour for specific antiviral applications.
The lead drug candidate NV-387 is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate is NV-HHV-1 for Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is the nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir. The company believes that since remdesivir is FDA-approved, the latter could be an approvable drug if safety is comparable.
NanoViricides is also developing drugs against various viral diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company’s platform technology is based on the TheraCour nanomedicine technology, licensed from AllExcel, and NanoViricides holds a worldwide exclusive perpetual license for several human viral diseases.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC.
